Jagsonpal Pharmaceuticals Ltd
Submission of Letter of Offer for Buy- Back upto 16,00,000 Equity Shares at price of INR-250/- per share amounting to INR-40,00,00,000/-
BUYBACK
▲ Positive Development
LOW RISK
📅 Filed on BSE: 06 May 2026, 08:13 PM IST · BSE ID: 5dc7c83b-2fca-4104-a9c4-7766dcc35c52
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released details for buying back its own shares, offering INR 250/- per share for a total of INR 40 Crore.
🤖 AI Summary
- Jagsonpal Pharmaceuticals submitted the Letter of Offer for its buyback program on May 06, 2026.
- Company to buy back up to 16,00,000 equity shares at INR 250/- per share.
- Aggregate buyback amount is up to INR 40,00,00,000/-, excluding transaction costs.
- This represents 2.38% of total paid-up share capital as of the May 04, 2026 Record Date.
- Buyback opening date is May 08, 2026; closing date is May 14, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Equity Shares to Buyback
16,00,000
Buyback Price per Equity Share
INR 250/-
Aggregate Buyback Amount
INR 40,00,00,000/-
Percentage of Paid-up Share Capital
2.38%
🏢 How This Affects the Company
The buyback will reduce the company's cash reserves by up to INR 40,00,00,000/-. It will also decrease the number of outstanding equity shares by 16,00,000, representing 2.38% of the total.
The buyback will utilize a portion of the company's free reserves and surplus for distribution to shareholders.
👥 What This Means For Shareholders
✅
Action Required
Eligible shareholders as of May 04, 2026, who wish to participate must tender their shares between May 08, 2026, and May 14, 2026.
👤
Who Is Affected
Shareholders holding Jagsonpal Pharmaceuticals equity shares as of the Record Date, May 04, 2026, are eligible to tender their shares on a proportionate basis.
🔍
Management Signal
The management's decision to proceed with the buyback signals an intent to return capital to shareholders and potentially optimize capital structure.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Buyback completion filing — verify actual shares bought back and total amount spent.
Subsequent quarterly results — assess cash reserve changes post-buyback.
Future capital allocation decisions — observe for further shareholder return initiatives.
LOW RISK
The filing is a procedural step for a previously announced buyback, confirming details and timeline.
💡 Investor Takeaway
Jagsonpal Pharmaceuticals confirmed the buyback offer of up to 16,00,000 equity shares at INR 250/- each, aggregating INR 40,00,00,000/-. This represents 2.38% of its paid-up share capital. The tender offer opens May 08, 2026, and closes May 14, 2026.
⚖️ Strengths & Concerns
✅ Positives
- Board-approved buyback plan for up to 16,00,000 equity shares, demonstrating commitment to capital return.
- Clear timeline established for tender offer, opening May 08, 2026, and closing May 14, 2026.
⚠️ Concerns
- The buyback will reduce the company's cash reserves by up to INR 40,00,00,000/-, impacting liquidity for future investments.
- Reduction of 2.38% in paid-up share capital may limit flexibility for future equity fundraising.
📅 Company Track Record
Jagsonpal Pharmaceuticals has been progressing with its buyback plans, with previous filings on March 12, 2026, announcing the buyback, and April 27, 2026, intimating the record date of May 04, 2026, and the formal board approval.
Based on publicly available historical data. For context only.